Hopper a regular unscrupulous raiser of capital. He has history of doing any deal possible with terrible terms many times at the peril of shareholders. He is seemingly unfamiliar and uncaring of the notion of shareholder value. CHM and RAD dying a slow and painful death from starvation by the looks, not a lot of hope for either longer term in my opinion. He will try his best no doubt for Imugene to buy them on their death beds, let’s see how much tolerance IMU shareholders have left for his corporate management, I say not very much. I suspect big pharma doesn’t want to do business with him, he seems to be on the nose unfortunately as no commercial deals presenting anywhere across his companies. Directors, staff and shareholders, alert yourselves, your chairman may be the main problem. A piece of advice for Mr. Hopper; start to put to bed some commercialisation of assets for shareholders, instead of endless dilution and reduction in shareholder value. Time is ticking.
RAD Price at posting:
6.4¢ Sentiment: None Disclosure: Not Held
